Overall, we have seen an increase in the use of dabigatran after the availability of idarucizumab. We should recognize, however, that we know that all 4 DOACs (direct oral anticoagulants) are ...

RESEARCH TRIANGLE, N.C., Aug. 25, 2026 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy ...

ORLANDO, Fla. (Reuters) - A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective ...

Agents that reverse the effect of direct oral anticoagulants (DOACs) are highly effective in patients with severe bleeding, but mortality rates remain high despite their use, a meta-analysis shows.

NEW ORLEANS — A reversal agent for the P2Y 12 inhibitor antiplatelet drug ticagrelor (Brilinta/Brilique, AstraZeneca) may soon be available after results of a new study showed immediate and sustained ...

Please provide your email address to receive an email when new articles are posted on . “The difference between ticagrelor and clopidogrel or prasugrel is that ticagrelor is a so-called reversible ...

Pleasanton, CA and Philadelphia, PA, Aug. 02, 2024 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who ...

A drug that reverses the blood thinning effects of factor Xa inhibitors effectively stopped acute life-threatening bleeding in patients taking a factor Xa inhibitor blood thinner drug, according to ...

NEW ORLEANS, LA—A novel, specific reversal agent for ticagrelor called PB2452 (PhaseBio) provides immediate and sustained reversal of the antiplatelet effects of the P2Y12 inhibitor as measured by ...

Michael B. Bottorff, PharmD: Fall risk is a major component of a discharge counseling strategy for patients who are newly being started on any anticoagulant, including a DOAC (direct oral ...